Cardiovascular Events in GnRH Agonist vs. Antagonist
Status:
Not yet recruiting
Trial end date:
2023-01-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test if the use of Degarelix for 1 year associated with a
lower rate of cardiovascular toxicity compared to Gonadotropin-releasing hormone (GnRH)
agonists in patients with advanced prostate cancer and cardiovascular risk factors, receiving
combination therapy of Androgen deprivation therapy (ADT) and second line hormonal or
chemotherapy?